Management of HBsAg-Positive, HBeAg-Negative, HBsAb-Nonreactive Patients

Disease Classification and Assessment

The American Association for the Study of Liver Diseases recommends that patients with HBsAg-positive, HBeAg-negative, HBsAb-nonreactive serological profile undergo initial evaluation, including HBV DNA quantification to determine viral load, liver function tests to assess inflammation, and assessment of liver fibrosis, as this profile indicates chronic HBV infection in the HBeAg-negative phase 1
HBeAg-negative chronic hepatitis B typically represents a later phase of infection with viral mutations that prevent HBeAg production despite ongoing viral replication, according to the European Association for the Study of the Liver 2
Initial evaluation should include screening for hepatocellular carcinoma if appropriate based on risk factors, as recommended by the American Association for the Study of Liver Diseases 2

The American Association for the Study of Liver Diseases recommends treatment if HBV DNA ≥2000 IU/mL with elevated liver enzymes, or if there is evidence of significant liver disease on biopsy, regardless of liver enzyme levels 1, 3
Treatment is also indicated if the patient has cirrhosis with any detectable HBV DNA, as recommended by the American Association for the Study of Liver Diseases 2, 4
The American Society of Clinical Oncology recommends that patients who require immunosuppressive therapy or chemotherapy receive antiviral prophylaxis regardless of HBV DNA level 5, 6

The American Association for the Study of Liver Diseases recommends first-line oral antiviral options, including entecavir 0.5 mg daily and tenofovir disoproxil fumarate 300 mg daily, as they have high barriers to resistance and potent viral suppression 1, 2
The European Association for the Study of the Liver recommends pegylated interferon alfa-2a as an alternative for selected patients who desire finite treatment duration, but notes that it has more side effects and contraindications 1, 3

The American Association for the Study of Liver Diseases recommends monitoring HBV DNA levels every 3 months until undetectable, then every 6 months, and checking liver enzymes every 3-6 months 2
Annual quantitative HBsAg testing is recommended to assess for potential HBsAg loss, as suggested by the European Association for the Study of the Liver 2

The American Association for the Study of Liver Diseases recommends long-term (indefinite) treatment for HBeAg-negative patients, as treatment can be discontinued if HBsAg loss occurs (functional cure), but this is rare in HBeAg-negative disease 1, 3
Discontinuation without HBsAg loss generally leads to virologic relapse, according to the European Association for the Study of the Liver 2

The American Society of Clinical Oncology recommends that patients who require immunosuppressive therapy or chemotherapy receive antiviral prophylaxis, which should be initiated at or before beginning immunosuppression and continued for at least 6-12 months after completing immunosuppressive therapy 5, 6
Regular surveillance for hepatocellular carcinoma is recommended for high-risk patients, such as those with cirrhosis, family history of HCC, or older age, as recommended by the American Association for the Study of Liver Diseases 2

The American Association for the Study of Liver Diseases recommends confirming HBsAg loss by repeating the test within 1-3 months to ensure this is not a laboratory error or transient fluctuation 7, 8
The American Association for the Study of Liver Diseases suggests continuing antiviral therapy for at least 12 months after confirmed HBsAg loss in non-cirrhotic patients, then considering discontinuation with close monitoring 9
The American Association for the Study of Liver Diseases advises continuing indefinite antiviral therapy even after HBsAg loss in cirrhotic patients due to the persistent risk of hepatocellular carcinoma and potential for severe hepatitis flares 9

The American Society of Clinical Oncology recommends monitoring ALT levels monthly for the first 3 months, then every 3 months thereafter to detect hepatitis flares early 10, 11
The American Society of Clinical Oncology suggests checking HBsAg and HBV DNA every 3 months for the first year, then every 6 months indefinitely 10, 12

The American Society of Clinical Oncology advises continuing antiviral prophylaxis for at least 12 months after cessation of immunosuppressive therapy (24 months for rituximab), regardless of HBsAg status 10, 11, 12

The American Society of Clinical Oncology recommends referring to or coordinating with a hepatologist experienced in HBV management to determine the optimal timing of treatment discontinuation and long-term monitoring strategy 10, 11, 12